Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer

16 Jan 2025

Abstract excerpt

Colorectal cancer (CRC) constitutes the second leading cause of cancer-related death worldwide and advanced CRCs are resistant to targeted therapies, chemotherapies and immunotherapies. p38α (Mapk14) has been suggested as a therapeutic target in CRC; however, available p38α inhibitors only allow for insufficient target inhibition. Here we describe a unique class of p38α inhibitors with ultralong target residence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Colorectal Cancer Treatments and Studies
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39820127
DOI: 10.1038/s43018-024-00899-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancerPMID 39820127Read ↗

A Special View of What Was Almost Forgotten: p38δ MAPKSemantic proximity Read ↗

A novel cell type-specific role of p38α in the control of autophagy and cell death in colorectal cancer cellsSemantic proximity Read ↗

Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.Semantic proximity Read ↗

A drug’s most potent target is not necessarily the source of its anti-cancer activitySemantic proximity Read ↗

MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancerSemantic proximity Read ↗

The emerging role of p38 alpha in cancer specific metabolism and therapy : analysis of autophagic and apoptotic pathways in response to its inhibitionSemantic proximity Read ↗

Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumorsSemantic proximity Read ↗

The p38 MAPK Components and Modulators as Biomarkers and Molecular Targets in CancerSemantic proximity Read ↗

Cytoplasmic p21 Mediates 5-Fluorouracil Resistance by Inhibiting Pro-Apoptotic Chk2Semantic proximity Read ↗

Oncogene-induced senescence and senescence-associated secretory phenotype (SASP) determine the efficacy of palbociclib in PIK3CA mutated colorectal cancerSemantic proximity Read ↗

Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancerSemantic proximity Read ↗

Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.